Net sales rose 3% in dollars to $14.4 billion, beating estimates, while core operating profit held flat at $5.94 billion ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it ...

Novartis said it returned to sales growth in the second quarter, as momentum from some of its key medicines and recent launches helped the company offset a hit from drugs that lost patent protection.

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Novartis said it returned to sales growth for the second quarter, after lower-priced competition in the U.S. for drugs that went off patent weighed on its top and bottom lines in prior quarters. Net ...

Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.

Analysts expect Novartis to make a core operating profit of $5.31 billion for the quarter, according to the same consensus. The company made $5.925 billion f ...

Swiss pharma giant Novartis AG NVS reported second-quarter core earnings per share (excluding one-time charges) of $2.41, ...

Find insight on Johnson & Johnson, Roche Holding, Novartis and more in the latest Market Talks covering health care.

Despite generic competition, Novartis returned to a growth trajectory in the second quarter. Management has confirmed its ...

Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...